Xenon Pharmaceuticals Inc. (XENE) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Xenon Pharmaceuticals Inc. (XENE): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 39/100 — a percentile rank of Xenon Pharmaceuticals Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| Market cap | $3.8B |
| EV / EBITDA | -8.3× |
| Return on equity | -32.9% |
| ROIC | -39.1% |
| Revenue growth | -100.0% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is Xenon Pharmaceuticals Inc. overvalued? P/B looks undervalued vs its 5-year range.
Independent of the events above — derived from Xenon Pharmaceuticals Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact